The Best Micro-Cap to Pandemic Proof Our Portfolios:
Forget Covid-19, this under-the-radar and recent IPO owns a platform capable of developing therapies to treat the current and future pandemics.
We’re starting out the year with a recommendation that combines two of the most powerful trends in the markets right now – micro-caps and biotech.
As I’ve shared in other write-ups, numerous tailwinds are combining to create a perfect storm for the smallest stocks to outperform in 2021. From surging retail investment to rising geopolitical risks to reawakened mergers & acquisitions activity.
Case in point: The small-cap Russell 2000 Index closed out the year by rallying seven out of eight weeks. And the Russell Microcap index is similarly surging.
In fact, since the market bottom earlier this year, micro-caps rallied a staggering 123%. That’s more than 60 full percentage points better than the performance of the large-cap S&P 500 Index.
Of course, these performance figures are merely the averages for the indexes. And we don’t invest in averages or indexes here.
Rather, we invest in individual micro-caps with the potential to soar 1,000% or more.
This time around, we’ve found an early stage biotech that could soar 1,500%, based on industry comps. Starting in a few weeks. Here are all the details…
This content is reserved for subscribers. For a limited time only you can use Coupon Code NEWYEAR to receive $395 off an annual subscription. Click here to subscribe.